Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2020 Feb 1;112(2):161-169.
doi: 10.1093/jnci/djz080.

Universal Tumor DNA BRCA1/2 Testing of Ovarian Cancer: Prescreening PARPi Treatment and Genetic Predisposition

Janet R Vos  1 , Ingrid E Fakkert  1 , Joanne A de Hullu  2 , Anne M van Altena  2 , Aisha S Sie  1 , Hicham Ouchene  1 , Riki W Willems  3 , Iris D Nagtegaal  3 , Marjolijn C J Jongmans  1 , Arjen R Mensenkamp  1 , Gwendolyn H Woldringh  1 , Johan Bulten  3 , Edward M Leter  4 , C Marleen Kets  1 , Michiel Simons  3 , Marjolijn J L Ligtenberg  1   3 , Nicoline Hoogerbrugge  1 ; OPA Working Group
Collaborators, Affiliations
Multicenter Study

Universal Tumor DNA BRCA1/2 Testing of Ovarian Cancer: Prescreening PARPi Treatment and Genetic Predisposition

Janet R Vos et al. J Natl Cancer Inst. .

Abstract

Background: Women with epithelial ovarian cancer (OC) have a higher chance to benefit from poly (ADP-ribose) polymerase inhibitor (PARPi) therapy if their tumor has a somatic or hereditary BRCA1/2 pathogenic variant. Current guidelines advise BRCA1/2 genetic predisposition testing for all OC patients, though this does not detect somatic variants. We assessed the feasibility of a workflow for universal tumor DNA BRCA1/2 testing of all newly diagnosed OC patients as a prescreen for PARPi treatment and cancer predisposition testing.

Methods: Formalin-fixed paraffin-embedded tissue was obtained from OC patients in seven hospitals immediately after diagnosis or primary surgery. DNA was extracted, and universal tumor BRCA1/2 testing was then performed in a single site. Diagnostic yield, uptake, referral rates for genetic predisposition testing, and experiences of patients and gynecologists were evaluated.

Results: Tumor BRCA1/2 testing was performed for 315 (77.6%) of the 406 eligible OC samples, of which 305 (96.8%) were successful. In 51 of these patients, pathogenic variants were detected (16.7%). Most patients (88.2%) went on to have a genetic predisposition test. BRCA1/2 pathogenic variants were shown to be hereditary in 56.8% and somatic in 43.2% of patients. Participating gynecologists and patients were overwhelmingly positive about the workflow.

Conclusions: Universal tumor BRCA1/2 testing in all newly diagnosed OC patients is feasible, effective, and appreciated by patients and gynecologists. Because many variants cannot be detected in DNA from blood, testing tumor DNA as the first step can double the identification rate of patients who stand to benefit most from PARP inhibitors.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Flowchart of the study showing the preferred universal tumor BRCA1/2 workflow on the left side in the dark boxes. n = 0 indicates that the test has been performed and no mutation was present. n = n/a indicates the test has not been performed or the test was unsuccessful and no result could be obtained. OC = epithelial ovarian cancer.
Figure 2.
Figure 2.
Uptake of universal BRCA1/2 tumor testing and referral for genetic predisposition testing over time. Error bars represent 95% confidence intervals.
See this image and copyright information in PMC

Comment in

References

    1. Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304(9):967–975. - PMC - PubMed
    1. Evans DG, Harkness EF, Howell A, et al. Intensive breast screening in BRCA2 mutation carriers is associated with reduced breast cancer specific and all cause mortality. Hered Cancer Clin Pract. 2016;14:8.. - PMC - PubMed
    1. National Comprehensive Cancer Network. Genetic/Familial High-Risk Assessment: Breast and Ovarian (Version I.2018 - October 3, 2017). 2018. https://www.nccn.org/professionals/physician_gls/PDF/genetics_screening.pdf. Accessed March 20, 2018.
    1. Arts-de Jong M, de Bock GH, van Asperen CJ, Mourits MJ, de Hullu JA, Kets CM.. Germline BRCA1/2 mutation testing is indicated in every patient with epithelial ovarian cancer: a systematic review. Eur J Cancer. 2016;61:137–145. - PubMed
    1. de Jonge MM, Ruano D, van Eijk R, et al. Validation and implementation of BRCA1/2 variant screening in ovarian tumor tissue. J Mol Diagn. 2018;20(5):600–611. - PubMed

Publication types

MeSH terms